On Mar. 27, 2025, the California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, announced it has approved new and amended funding program concepts which set the stage for providing up to $425 million in scientific research funding across discovery, preclinical and clinical research funding pillars.

The CIRM governing board also approved awarding $26.5 million to fund three projects aimed at addressing various conditions, including Angelman syndrome, a drug-resistant form of epilepsy, and graft-versus-host disease prevention.

The awards will support projects in the Agency’s late-stage preclinical and clinical programs, which provide funding for eligible stem cell and gene therapy-based projects through Investigational New Drug (IND)-clearance and all stages of clinical trial development. These awards bring the number of CIRM-funded clinical trials to 115.

Additionally, the Board approved an updated funding concept for Community Care Centers of Excellence (CCCE), which aims to expand access to regenerative medicine treatments across California.